Regardless the type of endograft used, there is a 10% decrease in CrCl in the first year after endovascular aneurysm repair. Suprarenal fixation does not seem to increase the likelihood of postoperative renal impairment. Decline in renal function over time after endovascular aortic repair is probably due to multiple factors, and measures known to be effective in protecting kidneys should be considered for these patients. Long-term follow-up with measurement of CrCl, along with renal imaging and regular blood pressure measurements, should be performed to detect possible late renal dysfunction. Prospective studies comparing suprarenal versus infrarenal fixation are needed to confirm those results.

At 1 year, endovascular repair with the MFM appears to be safe and effective while successfully maintaining branch vessel patency. Follow-up is ongoing.

EVAR of ruptured AAA is feasible for selected patients based on haemodynamic and morphologic criteria, and should be associated with improved immediate outcomes as compared with OR. These results should be tempered by the fact that these patients have heavy comorbidities which explains the absence of difference in mid-term mortality rates between the two groups, but should also encourage surgical institutions that are managing such life-threatening emergencies to introduce EVAR as part of their therapeutic arsenal for ruptured AAA.

Iliac fixation, along with proximal aortic fixation, is an important factor in preventing the migration of stent grafts that have longitudinal columnar support. Patients with good iliac fixation did not experience migration even in the presence of suboptimal proximal aortic fixation. Close proximity of the distal end of the stent graft to the iliac bifurcation seems to provide stability against migration.

Background COVID‐19 is a respiratory disease associated to thrombotic outcomes with coagulation and endothelial disorders. Based on that, several anticoagulation (AC) guidelines have been proposed. We aimed to identify if AC therapy modifies the risk of developing severe COVID‐19. Methods and Results COVID‐19 patients initially admitted in medical wards of 24 French hospitals were included prospectively from February 26th to April 20th, 2020. We used Poisson regression model, Cox proportional hazard model and matched propensity score to assess the effect of AC on outcomes (intensive care unit (ICU) admission and/or in‐hospital mortality). Study enrolled 2878 COVID‐19 patients, among whom 382 (13.2%) were treated with oral AC therapy prior to hospitalization. After adjustment, AC therapy prior to hospitalization was associated with a better prognosis with an adjusted Hazard Ratio (aHR) 0.70 (95% CI 0.55‐0.88). Analyses performed using propensity score matching confirmed that AC therapy prior to hospitalization was associated with a better prognosis with an aHR of 0.43 (95% CI 0.29–0.63) for ICU admission and aHR of 0.76 (95% CI 0.61–0.98) for composite criteria ICU admission and/or death. In contrast, therapeutic or prophylactic low or high dose AC started during hospitalization were not associated with any of the outcomes. Conclusions AC therapy used prior to hospitalization in medical wards was associated with a better prognosis in contrast to AC initiated during hospitalization. AC therapy introduced in early step of disease could better prevent COVID‐19‐associated coagulopathy, endotheliopathy and prognosis.